At the time of CAI’s investment, Aster-Cephac, based in Paris, France, was a contract research organization specializing in providing clinical pharmacology and bioanalytical services to the international pharmaceutical, biotechnology and medical device industries. Aster-Cephac enabled its clients to maximize the profitability of products during the period of exclusivity by offering high-quality, value-added services designed to reduce drug development time. CAI sold its position in Aster-Cephac to a strategic buyer.
Industry
Healthcare
Location
Paris, France
Date
CAI Fund I
1996
